{
    "id": 32641,
    "fullName": "EGFR G796D",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EGFR G796D lies within the protein kinase domain of the Egfr protein (UniProt.org). G796D has been demonstrated to occur as a secondary drug resistance mutation and results in increased cell proliferation (PMID: 28572531), and therefore, is predicted to lead to a gain of Egfr protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17930,
                    "pubMedId": 28572531,
                    "title": "EGFR G796D mutation mediates resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28572531"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "G796D",
    "createDate": "02/20/2020",
    "updateDate": "02/25/2020",
    "referenceTranscriptCoordinates": {
        "id": 188068,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181396G>A",
        "cDna": "c.2387G>A",
        "protein": "p.G796D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20574,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, post treatment biopsy analysis of a non-small cell lung cancer patient initially harboring EGFR T790M and EGFR L858R who demonstrated resistance to treatment with Tagrisso (osimertinib) revealed loss of T790M and L858R, but acquisition of EGFR G796D, and preclinical studies of cells expressing G796D demonstrated resistance to treatment with Tagrisso (osimertinib) in culture (PMID: 28572531).",
            "molecularProfile": {
                "id": 35239,
                "profileName": "EGFR G796D"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17930,
                    "pubMedId": 28572531,
                    "title": "EGFR G796D mutation mediates resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28572531"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35239,
            "profileName": "EGFR G796D",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188068,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181396G>A",
            "cDna": "c.2387G>A",
            "protein": "p.G796D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}